ClinicalTrials.gg
RecruitingNCT02447874R34 pK/PDUpdated Jul 29, 2026

Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

A Phase 1/2 interventional study of Arginine and Arginine (Loading) in Sickle Cell Disease, sponsored by Emory University. Recruiting at 2 sites in United States. Open to participants aged 7 Years to 21 Years. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Emory University · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
7 Years to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Anemia, Sickle Cell by Emory University — 4 open to participants now, 6 under way, none of them phase 3. Anemia, Sickle Cell · Emory University.

Planned enrollment
16th of 25
21 · median 24
Started
2015
with 1 other
Phase 1/2
Only one
of the 29
Registered
12th of 29
by date

Among the 29 studies in Anemia, Sickle Cell by Emory University, this one is the 16th largest by planned enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2015, is the only one in phase 1/2, and was the 12th registered.

Anemia, Sickle Cell

1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

4 of the 29 studies in Anemia, Sickle Cell by Emory University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 7 Years to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Anemia, Sickle Cell by Emory University, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether giving extra arginine to patients with sickle cell disease seeking treatment for vaso-occlusive painful events (VOE) will decrease pain scores, decrease need for pain medications or decrease length of hospital stay or emergency department visit.

Read the detailed description

Arginine is a simple amino acid that is found in many foods and is part of the proteins in a human's body. Patients with sickle cell disease have low levels of the amino acid arginine and these low levels may be related to pain episodes. Increasing levels of arginine in the blood may lower pain and/or lower the amount of pain medication (like morphine) that is needed to treated them. It may also decrease the amount of time spent in the hospital.

Available data suggest that, L-arginine is a safe \& efficacious intervention with narcotic-sparing effects in pediatric SCD patients with VOE. The addition of a higher loading dose to the standard dose or use of a continuous infusion may provide additional clinical benefits by overcoming multiple mechanisms that limit global arginine bioavailability in SCD.

03

Conditions studied

  • Sickle Cell Disease

Browse trials for

04

Who can participate

Ages eligible
7 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Established diagnosis of sickle cell disease-- SS (Hb-SS) or Sβᴼ-thalassemia
  • 7-21 years of age
  • Weight >= 25kg (55lbs)
  • Pain requiring medical care in an acute care setting (emergency department (ED), hospital ward, day hospital, clinic) requiring parenteral opioids, not attributable to non-sickle cell causes.

Exclusion criteria

Exclusion Criteria:

  • Decision to discharge home from acute care setting.
  • Diagnosis of sickle cell disease with any of the following types: SC disease (HbSC), hemoglobin beta thalassemia (Hb-Beta Thal), hemoglobin SD disease (HbSD), hemoglobin SE disease (HbSE), hemoglobin SO disease (HbSO), hemoglobin AS carrier (Hb AS)
  • Hemoglobin less than 5 gm/dL
  • Immediate Red cell transfusion anticipated
  • Renal dysfunction: Creatinine >1.0 or 2 x baseline
  • Mental status or neurological changes
  • Acute stroke or clinical concern for stroke
  • Pregnancy
  • Allergy to arginine
  • Previous hospitalization \< 7 days
  • Use of inhaled nitric oxide, sildenafil or arginine within the last 14 days
  • Not an appropriate candidate in the investigator's judgement
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
21 participants (estimated)

Study arms

  • Experimental
    Standard dose

    Subjects with sickle cell disease (SCD) and vaso-occlusive painful events (VOE) will be randomized to receive an intravenous (IV) infusion of a standard dose of arginine (100 mg/kg) three times a day for seven days or until discharged from the hospital, whichever occurs first

    Drug: Arginine

  • Experimental
    Loading dose + standard dose

    Subjects with sickle cell disease and vaso-occlusive painful events (VOE) will be randomized to receive an intravenous (IV) infusion of an initial loading dose of arginine (200 mg/kg) given over 30 minutes and then receive an intravenous (IV) infusion of a standard dose of arginine (100 mg/kg) three times a day for seven days or until discharged from the hospital, whichever occurs first

    Drug: Arginine · Drug: Arginine (Loading)

  • Experimental
    Loading dose + continuous infusion

    Subjects with sickle cell disease and vaso-occlusive painful events (VOE) will be randomized to receive an intravenous (IV) infusion of an initial loading dose of arginine (200 mg/kg) given over 30 minutes and then receive a continuous intravenous (IV) infusion of 300 mg/kg/24hr for 7 days or until discharged from the hospital, whichever occurs first

    Drug: Arginine (Loading) · Drug: Arginine (Continuous)

  • Experimental
    Non-Randomized Loading dose 500 mg/kg + standard dose

    Arginine will be dispensed intravenously (in the vein) as an initial bolus (loading) arginine dose at 500 mg/kg once, followed by a standard dose of 100mg/kg every 8 hours until discharge or for a total of 21 doses of arginine, whichever comes first.

    Drug: Arginine (Loading)

  • Experimental
    Non-Randomized Loading dose 300 mg/kg + standard dose

    Arginine will be dispensed intravenously (in the vein) as an initial bolus (loading) arginine dose at 300 mg/kg once, followed by a standard dose of 100mg/kg every 8 hours until discharge or for a total of 21 doses of arginine, whichever comes first.

    Drug: Arginine (Loading)

  • Experimental
    Non-Randomized Loading dose 400mg/kg + standard dose

    Arginine will be dispensed intravenously (in the vein) as an initial bolus (loading) arginine dose at 400 mg/kg once, followed by a standard dose of 100mg/kg every 8 hours until discharge or for a total of 21 doses of arginine, whichever comes first.

    Drug: Arginine (Loading)

Interventions

  • Arginine will be dispensed intravenously (in the vein) in the standard dose of arginine as 100 mg/kg three times a day for seven days or until discharge. * Loading dose: 200 mg/kg once * Continuous IV: 300 mg/kg/24 hours

    Also known as: Arginine Hydrochloride Injection, R-Gene® 10

  • DrugArginineStudies of ArginineArginine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Arginine will be dispensed intravenously (in the vein) as an initial bolus (loading) at each specified group dose once, followed by a standard dose of 100mg/kg every 8 hours until discharge or for a total of 21 doses of arginine, whichever comes first.

    Also known as: Arginine Hydrochloride Injection, R-Gene® 10

  • DrugArginineStudies of ArginineArginine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Arginine will be dispensed intravenously (in the vein) as a continuous IV infusion of 300 mg/kg/24hr

    Also known as: Arginine Hydrochloride Injection, R-Gene® 10

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics of IV arginine, measured by plasma arginine concentration over time

    Total time plasma arginine levels are maintained above the half-saturating concentration (Km) of cationic amino acid transporter protein-1 (CAT-1), which is 150 µM (normal range of extracellular plasma arginine concentration). pK samples will be collected at 6 time-points within 8 hours: prior to arginine treatment (time 0), and at 60, 90, 120 minutes, 4 and 8 hours after the initiation of arginine therapy, and then every 24 hours up to 7 days.

    Time frame: Day 1 through study completion, an average of up to 7 days

  2. Change in nitric oxide metabolites

    The formation of NO metabolites will be measured by determination of its stable end products in serum; nitrite (NO2-) and nitrate (NO3-). Change in nitric oxide metabolites will be calculated as the difference in metabolites from the time prior to arginine treatment (baseline) to the end of the intervention period.

    Time frame: Baseline, day 1 through study completion, an average of up to 7 days

Secondary outcomes

  1. Area Under the Plasma Concentration -Time Curve (AUC) From Time 0 to the Time of the Last Quantifiable Concentration for Arginine

    AUC is derived from drug concentration and time so it gives a measure of how much and how long a drug stays in a body. AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC\[0-tlqc\])

    Time frame: Day 1

  2. Maximum observed plasma concentration of arginine

    Maximum measured concentration of the arginine in plasma

    Time frame: Day 1

  3. Apparent clearance of arginine

    The clearance of a drug measures the rate at which the drug is removed from the body after the dose. Clearance of arginine after intravenous administration on day 1.

    Time frame: Day 1

  4. Terminal elimination half-life (t1/2) for arginine

    Terminal phase elimination half-life (t1/2) is the time required for half of the drug to be eliminated from the plasma.

    Time frame: Day 1

  5. Change in red blood cell (RBC) arginine

    Change in rbc arginine will be calculated as rbc arginine at the end of arginine administration minus rbc arginine at baseline.

    Time frame: Baseline, day 1 through study completion, an average of up to 7 days

  6. Daily urine arginine

    Total amount of arginine excreted in urine daily

    Time frame: From Day 1 until study completion, an average of up to 7 days

  7. Global arginine bioavailability (GABR)

    GABR represents a measure of endothelial function. GABR will be calculated by arginine divided by the sum of ornithine plus citrulline \[arginine/(ornithine+citrulline)\].

    Time frame: From enrollment through study completion, an average of up to 7 days

  8. Change in asymmetric dimethylarginine (ADMA) levels

    ADMA is is a metabolic by-product of continual protein modification processes and interferes with L-arginine in the production of nitric oxide. Change in ADMA levels will be calculated as ADMA levels at the end of arginine administration minus ADMA levels at baseline.

    Time frame: Baseline, day 1 and through study completion, an average of up to 7 days

  9. Modeling nitric oxide (NOx) level versus plasma arginine level

    Modeling nitric oxide (NOx) level versus plasma arginine level will be measured.

    Time frame: From enrollment through study completion, an average of up to 7 days

  10. Biomarkers of hemolysis

    Biomarkers of hemolysis (lactate dehydrogenase, hemoglobin, reticulocytes, arginase, indirect bilirubin) represent intravascular hemolysis and nitric oxide bioavailability.

    Time frame: From enrollment through study completion, an average of up to 7 days

  11. Erythrocyte glutathione levels

    Erythrocyte glutathione is a biomarker for oxidative stress. It will be measured by using liquid chromatography.

    Time frame: From enrollment through study completion, an average of up to 7 days

  12. Level of cytokines

    Cytokines are biomarkers for inflammation. Cell supernatants will be collected and analyzed for different cytokines.

    Time frame: From enrollment through study completion, an average of up to 7 days

07

Study locations

2 of 2 sites recruiting
  • Children's Healthcare fo Atlanta at Hughes Spalding
    Atlanta, Georgia 30303, United States
    Recruiting
  • Children's Healthcare of Atlanta at Arthur M. Blank Hospital
    Atlanta, Georgia 30329, United States
    Recruiting
08

References and documents

Publications

  • Morris CR, Brown LAS, Reynolds M, Dampier CD, Lane PA, Watt A, Kumari P, Harris F, Manoranjithan S, Mendis RD, Figueroa J, Shiva S. Impact of arginine therapy on mitochondrial function in children with sickle cell disease during vaso-occlusive pain. Blood. 2020 Sep 17;136(12):1402-1406. doi: 10.1182/blood.2019003672. PubMed 32384147 ↗
  • Korman R, Hatabah D, Brown LA, Harris F, Wilkinson H, Rees CA, Bakshi N, Archer DR, Dampier C, Morris CR. Impact of arginine therapy on kyotorphin in children with sickle cell disease and vaso-occlusive pain. Blood Adv. 2024 Jun 25;8(12):3267-3271. doi: 10.1182/bloodadvances.2023012209. PubMed 38527291 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2015, a primary completion of Jan 2028 and a completion of Jan 2028. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2015
First posted
May 19, 2015
Start
May 2015
Primary completionEst.
Jan 2028
CompletionEst.
Jan 2028
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02447874
Lead sponsor
Emory University
Collaborators
Children's Healthcare of Atlanta, National Center for Complementary and Integrative Health (NCCIH)
Responsible party
Claudia R. Morris (Professor, Emory University) — Principal investigator
First posted
May 19, 2015
Start date
May 2015
Primary completion
Jan 2028 (estimated)
Completion
Jan 2028 (estimated)
Last update
Jul 29, 2026

Study contacts

Reshika Mendis, MBBS
Contact
Reshika.mendis@choa.org
404-785-4525
Claudia Morris, MD
Contact
claudia.r.morris@emory.edu
404 727-5500
Claudia Morris, MD
principal investigator · Emory University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Arginine

Start the discussion